KEY FACULTY INTERVIEWS
What’s new in the field of small molecules for treatment of rheumatoid arthritis?
How can one choose among the range of JAK inhibitors given the increasing number of agents that are now available?
What is the future of Bruton’s tyrosine kinase inhibitors in rheumatic disease?
What new evidence is available about targeting of the IL-23 axis in psoriatic arthritis?
What evidence is of particular interest focusing on non-radiographic axial spondylarthritis?
How do different biologic agents perform on fatigue, pain, and work-related outcomes?
What therapeutic approaches did you present at ACR for extrarenal lupus erythematosus?
What agents have you been studying for lupus nephritis?
What are some of the most exciting developments in therapeutics presented at ACR 2019?
How will the new ACR guidelines on vaccination change daily practice?
What is changing regarding new outcome measures in rheumatic diseases?
What are the most promising therapeutic approaches recently evaluated in systemic sclerosis?
What key findings have been reported in recent trials on targeted therapy for systemic sclerosis?
What is new in the field of stem cell therapy in systemic sclerosis?
What was the rationale for your study on imaging outcomes in axial spondylarthritis?
What were the key findings of your study?
What new guidance does EULAR offer on the use of mobile health applications (apps) in people with rheumatic and musculoskeletal diseases?
What is the evidence regarding the long-term performance of biosimilars in rheumatoid arthritis?
How do JAK inhibitors compare to TNF inhibitors in psoriatic arthritis?
What is the main advantage of an inhibitor of the IL-17 axis rather than an anti-TNF in psoriatic arthritis?
What were the main findings from the Cardiovascular Inflammation Reduction Trial (CIRT) regarding methotrexate-related adverse events?
How do the results on methotrexate liver toxicity from your large randomized trial apply to daily practice?
What are your views on pain management with opioids in patients with rheumatic diseases?
What is the performance of JAK inhibitors on pain in rheumatoid arthritis?
Are there any updates on the use of hydroxychloroquine for rheumatoid arthritis?
Are there new developments in the etiology of rheumatoid arthritis with focus on the lung?